Yeji

$TYRA

Tyra Biosciences, Inc.

Runway:8 mo
NasdaqMarket cap: —CIK 0001863127

Upcoming catalysts

0 surfaced

No catalysts surfaced for TYRA yet.

Drug pipeline

TYRA-300 60mg
Low-grade NMIBC
TYRA-300-B01
Healthy
TYRA-300 0.125 mg/kg
Achondroplasia
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles
Locally Advanced Cholangiocarcinoma
Dabogratinib (TYRA-300) 60mg
Low Grade Upper Tract Urothelial Carcinoma
TYRA-430
Metastatic Hepatocellular Carcinoma
TYRA-300
Locally Advanced Urothelial Carcinoma

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT07265947Dabogratinib (TYRA-300) 60mgPhase 2Recruiting2030-10-01
NCT06842355TYRA-300 0.125 mg/kgPhase 2Recruiting2030-01-01
NCT06995677TYRA-300 60mgPhase 2Recruiting2028-02-01
NCT06915753TYRA-430Phase 1Recruiting2028-01-01
NCT05544552TYRA-300Phase 2Active Not Recruiting2026-11-01
NCT06160752Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cyclesPhase 1Recruiting2026-09-01
NCT06006702TYRA-300-B01Phase 1Active Not Recruiting2025-05-01